GlassScriptPhysician profile
John Weathers
NPI 1790134021
$2,551.88
in general payments reported to CMS, 2019-2025
18 companies · $691 in 2025
The $691 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2022: $540 · 2023: $716 · 2024: $483 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.94 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Oyster Point Pharma, INC. | $252.80 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $252.18 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $198.15 | 2024-2025 | Kxl System (Not Refurbished), Idose, Idosetr |
| Astellas Pharma US INC | $192.31 | 2023-2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $180.92 | 2022-2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $160.16 | 2019-2024 | Acuvue |
| Harrow Eye, LLC | $148.56 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $124.74 | 2023 | Tepezza |
| Alcon Vision LLC | $121.60 | 2022-2025 | Rocklatan, Tryptyr, Simbrinza |
| Amgen INC. | $119.84 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $82.68 | 2023-2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $75.35 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $59.45 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $57.69 | 2024 | Xdemvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $20.80 | 2023 | Biofinity Contact Lens |
| Biotissue Holdings INC. | $18.28 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Weathers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.